Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016

[1]  A. Levin,et al.  Are antimicrobial stewardship programs effective strategies for preventing antibiotic resistance? A systematic review , 2018, American journal of infection control.

[2]  M. Taljaard,et al.  The evolving epidemiology of Clostridium difficile infection in Canadian hospitals during a postepidemic period (2009–2015) , 2018, Canadian Medical Association Journal.

[3]  P. Moayyedi,et al.  Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection , 2018, Official Journal of the Association of Medical Microbiology and Infectious Disease Canada.

[4]  E. Cordero,et al.  Long-Term Impact of an Educational Antimicrobial Stewardship Program on Hospital-Acquired Candidemia and Multidrug-Resistant Bloodstream Infections: A Quasi-Experimental Study of Interrupted Time-Series Analysis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Jernigan,et al.  Association of Hospital-Onset Clostridium difficile Infection Rates and Antibiotic Use in US Acute Care Hospitals, 2006–2012: An Ecologic Analysis , 2017, Open Forum Infectious Diseases.

[6]  Daniel J. Wilson,et al.  Effects of control interventions on Clostridium difficile infection in England: an observational study , 2017, The Lancet. Infectious diseases.

[7]  G. Garber,et al.  Variability in antibiotic use across Ontario acute care hospitals , 2017, The Journal of antimicrobial chemotherapy.

[8]  I. Gould,et al.  Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis. , 2017, The Lancet. Infectious diseases.

[9]  Xiaoming Sheng,et al.  Antibiotic Use in Small Community Hospitals. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Leibovici,et al.  Systematic review of antibiotic consumption in acute care hospitals. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  M. Bassetti,et al.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. , 2015, The Journal of antimicrobial chemotherapy.

[12]  John M Conly,et al.  Assessment of Antimicrobial Utilization Metrics: Days of Therapy Versus Defined Daily Doses and Pharmacy Dispensing Records Versus Nursing Administration Data , 2015, Infection Control & Hospital Epidemiology.

[13]  D. Gravel,et al.  Prevalence of antimicrobial use in a network of Canadian hospitals in 2002 and 2009 , 2015, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[14]  J. Karlowsky,et al.  Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals. , 2013, The Journal of antimicrobial chemotherapy.

[15]  Á. Soriano,et al.  Influence of Multidrug Resistance and Appropriate Empirical Therapy on the 30-Day Mortality Rate of Pseudomonas aeruginosa Bacteremia , 2012, Antimicrobial Agents and Chemotherapy.

[16]  R. Porcher,et al.  Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study. , 2012, The Journal of antimicrobial chemotherapy.

[17]  R. Cantón,et al.  Emergence and spread of antibiotic resistance following exposure to antibiotics. , 2011, FEMS microbiology reviews.

[18]  R. Leclercq,et al.  Hospital-wide modification of fluoroquinolone policy and meticillin-resistant Staphylococcus aureus rates: a 10-year interrupted time-series analysis. , 2011, The Journal of hospital infection.

[19]  B. Limbago,et al.  Complete Restriction of Fluoroquinolone Use to Control an Outbreak of Clostridium difficile Infection at a Community Hospital , 2009, Infection Control & Hospital Epidemiology.

[20]  L. Valiquette,et al.  Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Burke,et al.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  R. Polk,et al.  Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Burke,et al.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship , 2007 .

[24]  D. Monnet,et al.  Discrepancies between prescribed daily doses and WHO defined daily doses of antibacterials at a university hospital. , 2006, British journal of clinical pharmacology.

[25]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[26]  M. Edmond,et al.  Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  K. Anstrom,et al.  Costs and Outcomes Among Hemodialysis-Dependent Patients With Methicillin-Resistant or Methicillin-Susceptible Staphylococcus aureus Bacteremia , 2005, Infection Control & Hospital Epidemiology.

[28]  J. Hurley.  Comparison of mortality associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: an ecological analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  S. Cosgrove,et al.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[31]  S. Cosgrove,et al.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.